Researchers delineate novel COVID-19 subgroups in critically ill patients
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
List view / Grid view
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
A new study has suggested that mucosal vaccines may reduce transmission of airborne viruses such as COVID-19 more than injectable vaccines.